Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
Scientific Reports|March 29, 2018
NF-kB2 Genetic Variations are Significantly Associated with Non-Small Cell Lung Cancer Risk and Overall SurvivalFoteinos-Ioannis D Dimitrakopoulos, Anna G Antonacopoulou, Anastasia E Kottorou, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2012
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trialK Pliarchopoulou, K T Kalogeras, R Kronenwett, et al.
BMC Cancer|February 22, 2014
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)George Pentheroudakis, Vassiliki Kotoula, Elena Fountzilas, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 2, 2004
The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survivalAthanassios C Tsamandas, Dimitrios Kardamakis, Panagiota Ravazoula, et al.
BMC Medicine|January 9, 2010
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group studyDimitrios Bafaloukos, Helena Linardou, Gerasimos Aravantinos, et al.
BMC Cancer|May 10, 2015
Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancerDimitrios Pectasides, Vasilios Karavasilis, George Papaxoinis, et al.
Anti-Cancer Drugs|May 29, 2004
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)Jim Janinis, George P Stathopoulos, Pavlos Nikolaidis, et al.
Acta Oncologica (Stockholm, Sweden)|May 18, 2021
AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group studyGeorge Zarkavelis, Epaminontas Samantas, Georgia-Angeliki Koliou, et al.
Medical Oncology (Northwood, London, England)|August 20, 2005
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II StudyGeorge Fountzilas, Christos Tolis, Anna Kalogera-Fountzila, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 14, 2005
Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II studyGeorge Fountzilas, Christos Tolis, Anna Kalogera-Fountzila, et al.
Pageof 11